Division 8 TOXICOLOGICAL INFORMATIONX1
United Kingdom
| COLUMN 1 STANDARD INFORMATION REQUIRED | COLUMN 2 SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1 |
|---|---|
| F18.1. Skin corrosion/irritation | 8.1. The study/ies do(es) not need to be conducted if:
If results from one of the two studies under point 8.1.1 or 8.1.2 already allow a conclusive decision on the classification of a substance or on the absence of skin irritation potential, the second study need not be conducted. |
| 8.1.1. Skin corrosion, in vitro | |
| 8.1.2. Skin irritation, in vitro | |
| 8.2. Serious eye damage/eye irritation | 8.2. The study/ies do(es) not need to be conducted if:
|
| 8.2.1. Serious eye damage/eye irritation, in vitro | 8.2.1. If results from a first in vitro study do not allow a conclusive decision on the classification of a substance or on the absence of eye irritation potential, (an)other in vitro study/ies) for this endpoint shall be considered. |
| X28.3. Skin sensitisation Information allowing:
| The study(ies) under point 8.3.1 and 8.3.2 do not need to be conducted if:
|
| 8.3.1. Skin sensitisation, in vitro/in chemico Information from in vitro/in chemico test method(s) recognised according to Article 13(3), addressing each of the following key events of skin sensitisation:
| The(se) test(s) do not need to be conducted if:
If information from test method(s) addressing one or two of the key events in column 1 already allows classification and risk assessment according to point 8.3, studies addressing the other key event(s) need not be conducted. |
| 8.3.2. Skin sensitisation, in vivo | An in vivo study shall be conducted only if in vitro/in chemico test methods described under point 8.3.1 are not applicable, or the results obtained from those studies are not adequate for classification and risk assessment according to point 8.3. The murine local lymph node assay (LLNA) is the first-choice method for in vivo testing. Only in exceptional circumstances should another test be used. Justification for the use of another in vivo test shall be provided. In vivo skin sensitisation studies that were carried out or initiated before 10 May 2017 , and that meet the requirements set out in Article 13(3), first subparagraph, and Article 13(4) shall be considered appropriate to address this standard information requirement. |
| 8.4. Mutagenicity | 8.4. Further mutagenicity studies shall be considered in case of a positive result. |
| F28.4.1. In vitro gene mutation study in bacteria | 8.4.1. The study does not need to be conducted for nanoforms where it is not appropriate. In this case other studies involving one or more in vitro mutagenicity study(ies) in mammalian cells (Annex VIII, sections 8.4.2. and 8.4.3 or other internationally recognised in vitro methods) shall be provided. |
| 8.5. Acute toxicity | 8.5. The study/ies do(es) not generally need to be conducted if:
|
| 8.5.1. By oral route | 8.5.1. The study need not be conducted if a study on acute toxicity by the inhalation route (8.5.2) is available. For nanoforms, a study by the oral route shall be replaced by a study by the inhalation route (8.5.2), unless exposure of humans via inhalation is unlikely, taking into account the possibility of exposure to aerosols, particles or droplets of an inhalable size. |
Annotations
Textual amendments
- F1
- F2
Editorial notes
- X1
- X2
Notes on the whole EU Regulation
Textual amendments
Notes on Annex VII
Textual amendments
Footnotes
- f1
-
This Annex shall apply to producers of articles that are required to register in accordance with Article 7 and to other downstream users that are required to carry out tests under this Regulation adapted as necessary.
- f2
-
Note: conditions for not requiring a specific test that are set out in regulations under Article 13(3) that are not repeated in column 2, also apply.